Impaired cardiac function or clinically significant cardiac disease.
Impaired cardiac function or clinically significant cardiac disease
Impaired cardiac function or clinically significant cardiac disease, including any of the following (Criteria a through g):
Impaired cardiac function
Impaired cardiac function or clinically significant cardiac disease.
Impaired cardiac function or clinically significant cardiac disease
Subject has any neuropathy > Grade . . Subject has impaired cardiac function or clinically significant cardiac diseases, including any of the following:
Clinically significant cardiac disease or impaired cardiac function
Impaired cardiac function or clinically significant cardiac disease.
Impaired cardiac function or clinically significant cardiac disease.
Impaired cardiac function.
Impaired cardiac function
Impaired cardiac function or clinically significant cardiac diseases
Participants with impaired cardiac function or clinically significant cardiac disease.
Impaired cardiac function or history of cardiac problems
Impaired heart function
Clinically significant cardiac disease or impaired cardiac function, including any of the following:
Patients who have impaired cardiac function or clinically significant cardiac diseases,
Impaired cardiac function or history of cardiac problems
Impaired cardiac function or clinically significant cardiac disease
Impaired cardiac function or clinically significant cardiac diseases, including any of the following:\r\n* Acute myocardial infarction or angina pectoris =<  months prior to starting study drug
Impaired cardiac function or clinically significant cardiac disease
Impaired cardiac function or clinically significant cardiac diseases, including any of the following:
Impaired cardiac function
Impaired cardiac function or clinically significant cardiac diseases, including any of the following:
Impaired cardiac function or clinically significant cardiac disease
Patients with impaired cardiac function or clinically significant cardiac disease.
Impaired cardiac function or clinically significant cardiac diseases.
Clinically significant cardiac disease or impaired cardiac function, including any of the following:
Impaired cardiac function (defined futher in the protocol)
Known impaired cardiac function including any one of the following:
Patients with impaired cardiac function or clinically significant cardiac diseases as defined by the protocol
Impaired cardiac function
Patients with impaired cardiac function or clinically significant cardiac disease:
Known impaired cardiac function or clinically significant cardiac disease
Impaired cardiac function, uncontrolled cardiac arrhythmias despite medications, or clinically significant cardiac disease
Clinically significant cardiac disease or impaired cardiac function
Patients must not have known impaired cardiac function or clinically significant cardiac disease
Impaired cardiac function or clinically significant cardiac diseases, including any of the following:
Impaired cardiac function or clinically significant cardiac diseases, including any of the following:
Impaired heart function
Impaired cardiac function
Impaired cardiac function or clinically significant cardiac diseases.
Impaired cardiac function or clinically significant cardiac diseases, including any of the following:
Impaired cardiac function
Clinically significant cardiac disease or impaired cardiac function
Impaired cardiac function or clinically significant cardiac diseases, including any of the following:
impaired cardiac function
Impaired cardiac function or clinically significant cardiac diseases
Impaired heart function
Impaired cardiac function including any of the following:
Impaired cardiac function or clinically significant cardiac diseases
Impaired cardiac function or clinically significant cardiac diseases
Impaired cardiac function
Impaired cardiac function or clinically significant cardiac disease
Impaired cardiac function including any one of the following:
